Applications and Potential of In Silico Approaches for Psychedelic Chemistry
Open accessThe DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
Abstract
Molecular-level investigations of the Central Nervous System have been revolutionized by the development of computational methods, computing power, and capacity advances. These techniques have enabled researchers to analyze large amounts of data from various sources, including genomics, in vivo, and in vitro drug tests. In this review, we explore how computational methods and informatics have contributed to our understanding of mental health disorders and the development of novel drugs for neurological diseases, with a special focus on the emerging field of psychedelics. In addition, the use of state-of-the-art computational methods to predict the potential of drug compounds and bioinformatic tools to integrate disparate data sources to create predictive models is also discussed. Furthermore, the challenges associated with these methods, such as the need for large datasets and the diversity of in vitro data, are explored. Overall, this review highlights the immense potential of computational methods and informatics in Central Nervous System research and underscores the need for continued development and refinement of these techniques and more inclusion of Quantitative Structure-Activity Relationships (QSARs).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Timeline of key events in computational psychedelic sciences [20,21].](https://figures.cochat.ai/paper-figures/9a50d515ec724e5f9299206e965ca211/applications-and-potential-of-in-silico-approaches-for-psychedelic-chemistry-figure-2.jpg)



![Figure 6 Schematic illustration of two proposed mechanisms of aromatic hydroxylation of Tyramine by Cpd 1, as proposed via (a) a Meisenheimer-complex mechanism and (b) a radical [65,66].](https://figures.cochat.ai/paper-figures/774eb1af2a954b6b8c8f5c46e0bdb61a/applications-and-potential-of-in-silico-approaches-for-psychedelic-chemistry-figure-6.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Structure-Activity Relationship (SAR) analysis plays a pivotal role too. It involves studying the relationship between the chemical structure of cosmetic ingredients and their biological activities.”
From The dark side of beauty: an in-depth analysis of the health hazards and toxicological impact of synthetic cosmetics and personal care products (2024) · cites this paper as [126]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In silico SAR models can predict the potential for a chemical to bind to specific receptors or enzymes, providing insights into mechanisms of action and potential health effects (126).”
From The dark side of beauty: an in-depth analysis of the health hazards and toxicological impact of synthetic cosmetics and personal care products (2024) · cites this paper as [126]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules
Cornell, W. D., Cieplak, P., Bayly, C. I., Gould, I. R., Merz, K. M., Ferguson, D. M., Spellmeyer, D. C., Fox, T., Caldwell, J. W., & Kollman, P. A. (1995) · Journal of the American Chemical Society · doi:10.1021/ja00124a002 · Cited by 13,103 · cited 1×
“Timeline of key events in computational psychedelic sciences [20,21].”
BackgroundDewar, M. J. S., Zoebisch, E. G., Healy, E. F., & Stewart, J. J. P. (1985) · Journal of the American Chemical Society · doi:10.1021/ja00299a024 · Cited by 13,074 · cited 1×
“Timeline of key events in computational psychedelic sciences [20,21].”
BackgroundComputational Methods in Drug Discovery
Sliwoski, G., Kothiwale, S., Meiler, J., & Lowe, E. W. (2014) · Pharmacological Reviews · doi:10.1124/pr.112.007336 · Cited by 2,160 · cited 2×
“…at that time, including that some therapeutic-related phenomena such as protein-protein interactions and/or protein-DNA interactions were formidable problems in part since the size of the systems was perhaps beyond, or at best at the limits, of the then generally available computational power [54].”
BackgroundPredicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667 · cited 2×
“The extent to which the power and potential of computational approaches have grown is illustrated by the highly cited study by Keiser et al. in 2009 [45].”
BackgroundEstimation of toxic hazard—A decision tree approach
Cramer, G. M., Ford, R. A., & Hall, R. L. (1976) · Food and Cosmetics Toxicology · doi:10.1016/s0015-6264(76)80522-6 · Cited by 1,570 · cited 1×
“…essential tool towards their treat-ment [68]. and valuable part of toxicology since the mid-1970s [73,74] and an extremely important part in the twenty-first century, as Cramer et al. published the first modern approach (intended primarily to prioritize structures for experimental evaluation) [75].”
BackgroundOxygen Activation and Radical Transformations in Heme Proteins and Metalloporphyrins
Huang, X., & Groves, J. T. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00373 · Cited by 1,037 · cited 1×
“…of dopamine synthesis, instead of following a traditional Meisenheimer-complex mechanism, the mechanism instead involves an initial hydrogen atom transfer from the phenolic hydroxyl group of the initial tyramine substrate to the iron-oxo of the π -cation radical ferryl-oxo compound (Cpd I) [66].”
BackgroundUltra-large library docking for discovering new chemotypes
Lyu, J., Wang, S., Balius, T. E., Singh, I., Levit, A., Moroz, Y. S., O’Meara, M. J., Che, T., Algaa, E., Tolmachova, K., et al. (2019) · Nature · doi:10.1038/s41586-019-0917-9 · Cited by 998 · cited 2×
“In 2019, Lyu et al. [55] examined possible ligands or leads for binding AmpC β -lactamase and the D4 dopamine receptor.”
BackgroundComputer-based de novo design of drug-like molecules
Schneider, G., & Fechner, U. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1799 · Cited by 948 · cited 1×
“The increasing power of computers coupled with computational method development has greatly expanded the potential of this approach for many fields, including the drug discovery process and computer-aided drug design (CADD) [40].”
Muratov, E. N., Bajorath, J., Sheridan, R. P., Tetko, I. V., Filimonov, D., Poroikov, V., Oprea, T. I., Baskin, I. I., Varnek, A., Roitberg, A., et al. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00098a · Cited by 913 · cited 1×
“In general, this objective can be achieved by an ensemble of single-task models or by a single model that can predict more than one activity simultaneously using non-neural or neural net-based techniques, including deep learning, which has become popular in recent years [77,81].”
BackgroundRethinking drug design in the artificial intelligence era
Schneider, P., Walters, W. P., Plowright, A. T., Sieroka, N., Listgarten, J., Goodnow, R. A., Fisher, J., Jansen, J. M., Duca, J. S., Rush, T. S., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0050-3 · Cited by 894
PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome
Kroeze, W. K., Sassano, M. F., Huang, X.-P., Lansu, K., McCorvy, J. D., Giguère, P. M., Sciaky, N., & Roth, B. L. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3014 · Cited by 755 · cited 1×
“For example, there are 97,622 Ki data for multiple CNS targets (e.g., receptors and transporters) available in one Psychoactive Drug Screening Program (PDSP) [91] database.”
BackgroundTeleanu, R. I., Niculescu, A.-G., Roza, E., Vladâcenco, O., Grumezescu, A. M., & Teleanu, D. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23115954 · Cited by 596 · cited 1×
“This neurotransmission process occurs through signal conduction via synapses from one neuron to another [2].”
BackgroundMolecular representations in AI-driven drug discovery: a review and practical guide
David, L., Thakkar, A., Mercado, R., & Engkvist, O. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00460-5 · Cited by 587 · cited 1×
“By leveraging its algorithms, researchers can analyze large-scale genomic data, in vivo and in vitro drug test results, and other diverse sources of information to uncover patterns, relationships, and predictive models [96–99].”
BackgroundHow artificial intelligence is changing drug discovery
Fleming, N. (2018) · Nature · doi:10.1038/d41586-018-05267-x · Cited by 546 · cited 1×
“By leveraging its algorithms, researchers can analyze large-scale genomic data, in vivo and in vitro drug test results, and other diverse sources of information to uncover patterns, relationships, and predictive models [96–99].”
BackgroundStructural Basis for Molecular Recognition at Serotonin Receptors
Wang, C., Jiang, Y., Ma, J., Wu, H., Wacker, D., Katritch, V., Han, G. W., Liu, W., Huang, X.-P., Vardy, E., et al. (2013) · Science · doi:10.1126/science.1232807 · Cited by 528 · cited 1×
“In 2013, Wang et al. reported a detailed study, now highly cited, that also at least in part involved Docking on 5-HT receptors [49], specifically a human 5-HT1B G protein-coupled However, this can also present challenges beyond fi nding a su ffi ciently well-resolved structure. protein-coupled…”
BackgroundHuman Pharmacology of MDMA: Pharmacokinetics, Metabolism, and Disposition
de la Torre, R., Farré, M., Roset, P. N., Pizarro, N., Abanades, S., Segura, M., Segura, J., & Camí, J. (2004) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200404000-00009 · Cited by 444 · cited 1×
“Multiple This is further enhanced where experimental data is available for comparison (e.g., structures, thermochemical values). mechanisms (e.g., reuptake inhibition and release) of drug-transporter complexes [69].”
BackgroundBaumann, M. H., Ayestas, M. A., Partilla, J. S., Sink, J. R., Shulgin, A. T., Daley, P. F., Brandt, S. D., Rothman, R. B., Ruoho, A. E., & Cozzi, N. V. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.304 · Cited by 439 · cited 1×
“4 of 20 Molecules 2023 , 28 , x FOR PEER REVIEW 4 of 21 interpreting trends, Structure-Activity Relationships, and the identi fi cation of some mechanisms of the CNS [17,24–27].”
BackgroundHealth, T. L. G. (2020) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30432-0 · Cited by 417
Artificial Intelligence in Drug Design
Hessler, G., & Baringhaus, K.-H. (2018) · Molecules · doi:10.3390/molecules23102520 · Cited by 373
The monoamine neurotransmitter disorders: an expanding range of neurological syndromes
Kurian, M. A., Gissen, P., Smith, M., Heales, S. J., & Clayton, P. T. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70141-7 · Cited by 351 · cited 1×
“Dopamine (DA) and serotonin (5-HT) have leading roles in the brain, including the control of locomotion, mood alteration, and behavior [4,5]. leading roles in the brain, including the control of locomotion, mood alteration, and behavior [4,5].”
BackgroundBath salts and synthetic cathinones: An emerging designer drug phenomenon
German, C. L., Fleckenstein, A. E., & Hanson, G. R. (2014) · Life Sciences · doi:10.1016/j.lfs.2013.07.023 · Cited by 348 · cited 1×
“Designer drugs are synthetic compounds developed to provide rewarding effects like illicit drugs of abuse while circumventing existing legislative classification and penalties [90].”
BackgroundJohnson, M. P., Hoffman, A. J., & Nichols, D. E. (1986) · European Journal of Pharmacology · doi:10.1016/0014-2999(86)90615-1 · Cited by 306
Psychedelics and the Human Receptorome
Ray, T. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009019 · Cited by 301 · cited 3×
“For the la tt er, it is notable that an ever-increasing number of experimental in For the latter, it is notable that an ever-increasing number of experimental in vitro studies on the CNS [33–38] could provide such invaluable data. vitro studies on the CNS [33–38] could provide such invaluable data.”
BackgroundDeep generative molecular design reshapes drug discovery
Zeng, X., Wang, F., Luo, Y., Kang, S.-G., Tang, J., Lightstone, F. C., Fang, E. F., Cornell, W., Nussinov, R., & Cheng, F. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100794 · Cited by 295
Stereochemistry in Drug Action
McConathy, J., & Owens, M. J. (2003) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v05n0202 · Cited by 294 · cited 2×
“Amphetamine MDMA (3,4-methylenedioxymethamphetamine) is one such species, with R-and S-MDMA being reported to exhibit different activities towards CNS targets [72,86–88].”
BackgroundA renaissance in trace amines inspired by a novel GPCR family
Lindemann, L., & Hoener, M. C. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.03.007 · Cited by 287 · cited 1×
“Dopamine (DA) and serotonin (5-HT) have leading roles in the brain, including the control of locomotion, mood alteration, and behavior [4,5]. leading roles in the brain, including the control of locomotion, mood alteration, and behavior [4,5].”
BackgroundMolecular Biology of Serotonin Receptors - Structure and Function at the Molecular Level
Kroeze, W., Kristiansen, K., & Roth, B. (2002) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026023393796 · Cited by 277 · cited 1×
“…and reliable the greater the similarity between the sequences of the ‘ unknown ’ target protein and those with known structures. receptor proteins [48], which can be thought of as front-line members of the CNS. High-resolution 3D X-Ray crystal structures are now available for most receptors,…”
BackgroundRecent Trends in Quantum Chemical Modeling of Enzymatic Reactions
Himo, F. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b02671 · Cited by 268 · cited 1×
“Mean-while, density functional (DFT) methods can be applied to chemical models of up to 200–300 heavy atoms [41].”
MethodDesigner drugs: mechanism of action and adverse effects
Luethi, D., & Liechti, M. E. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02693-7 · Cited by 262 · cited 1×
“Since there is a direct relationship between the chemical processes in the CNS and these diseases, a deeper understanding of the molecular mechanism would enhance prevention and treatment [7,8].”
BackgroundA comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer’s disease agents: A review
Manzoor, S., & Hoda, N. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112787 · Cited by 248 · cited 2×
“The concentration of the neurotransmi tt ers in the brain (more speci fi cally, their relative proportions in a vesicle, synapse, and synaptic cleft) relates to the biochemical pathology of numerous neurological disorders, including depression, anxiety, and post-traumatic stress disorder (PTSD) [6].”
BackgroundStructure–Activity Relationships of One-Ring Psychotomimetics
SHULGIN, A. T., SARGENT, T., & NARANJO, C. (1969) · Nature · doi:10.1038/221537a0 · Cited by 244 · cited 1×
“…bioinformatics data analysis is now seen as an essential tool towards their treat-ment [68]. and valuable part of toxicology since the mid-1970s [73,74] and an extremely important part in the twenty-first century, as Cramer et al. published the first modern approach (intended primarily to…”
BackgroundThe Directive of the Protein: How Does Cytochrome P450 Select the Mechanism of Dopamine Formation?
Schyman, P., Lai, W., Chen, H., Wang, Y., & Shaik, S. (2011) · Journal of the American Chemical Society · doi:10.1021/ja201665x · Cited by 234
The Background and Chemistry of MDMA
Shulgin, A. T. (1986) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1986.10472361 · Cited by 233 · cited 2×
“Despite Shulgin reporting experime tal SAR data on MDMA and other psychedelic compounds almost 50 years ago [15], a gre ter understanding of MDMA’s biochemical i teractions and ffects is also inhibited by the scarcity f reliable experimental evidence elucidating these phenomena at the molecular level.”
BackgroundThe promises and perils of psychedelic pharmacology for psychiatry
McClure-Begley, T. D., & Roth, B. L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00421-7 · Cited by 194
Multiscale methods in drug design bridge chemical and biological complexity in the search for cures
Amaro, R. E., & Mulholland, A. J. (2018) · Nature Reviews Chemistry · doi:10.1038/s41570-018-0148 · Cited by 177 · cited 4×
“It is noted that for each, there are many recent thorough and detailed reviews [42,67].”
BackgroundInfluentialMulti-Parameter Optimization: Identifying High Quality Compounds with a Balance of Properties
D. Segall, M. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799436430 · Cited by 172 · cited 1×
“In general, this objective can be achieved by an ensemble of single-task models or by a single model that can predict more than one activity simultaneously using non-neural or neural net-based techniques, including deep learning, which has become popular in recent years [77,81].”
BackgroundPirintsos, S., Panagiotopoulos, A., Bariotakis, M., Daskalakis, V., Lionis, C., Sourvinos, G., Karakasiliotis, I., Kampa, M., & Castanas, E. (2022) · Molecules · doi:10.3390/molecules27134060 · Cited by 167 · cited 1×
“As a result, in silico docking, which can be coupled with other methods (e.g., MD, QSAR, etc.), has greatly advanced in just a few years as a promising approach for the screening of chemical space and subsequent design of a possible therapeutic compound for a given disease [56].”
BackgroundQuantum Mechanics/Molecular Mechanics Modeling of Enzymatic Processes: Caveats and Breakthroughs
Quesne, M. G., Borowski, T., & de Visser, S. P. (2016) · Chemistry – A European Journal · doi:10.1002/chem.201503802 · Cited by 160 · cited 2×
“It is noted that for each, there are many recent thorough and detailed reviews [42,67].”
BackgroundIllumination of serotonin transporter mechanism and role of the allosteric site
Yang, D., & Gouaux, E. (2021) · Science Advances · doi:10.1126/sciadv.abl3857 · Cited by 149 · cited 4×
“Yang and Gouaux [14] have experimentally investigated the molecular mechanism of ion-coupled serotonin reuptake by hSERT, with some standard modeling used to help re-fine the structures obtained.”
BackgroundMethodInfluentialCatalytic Mechanism of Dopamine β-Monooxygenase Mediated by Cu(III)−Oxo
Yoshizawa, K., Kihara, N., Kamachi, T., & Shiota, Y. (2006) · Inorganic Chemistry · doi:10.1021/ic0521168 · Cited by 134 · cited 1×
“With regards to CNS-relevant studies, Kamachi et al. [63] and Yoshizawa, K. [64] used homology modeling to construct suitable protein templates and subsequent QM/MM studies (as well as some QM-cluster studies) to investigate the catalytic mechanism of dopamine-monooxygenase (DBM).”
MethodHofmaier, T., Luf, A., Seddik, A., Stockner, T., Holy, M., Freissmuth, M., Ecker, G. F., Schmid, R., Sitte, H. H., & Kudlacek, O. (2014) · Neurochemistry International · doi:10.1016/j.neuint.2013.11.010 · Cited by 117 · cited 1×
“For example, Hofmaier et al. [57] used homology modeling, docking, and DFT calculations, along with experiments, to identify the residues of the central binding sites of MATs involved in binding neutral and protonated levamisole.”
MethodMonoamine transporters: structure, intrinsic dynamics and allosteric regulation
Cheng, M. H., & Bahar, İ. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0253-7 · Cited by 113 · cited 1×
“Similarly, Cheng and Bahar [61] have discussed progress in the elucidation of the structural dynamics of MATs and their conformational landscape and transitions, as well as allosteric regulation mechanisms [61].”
BackgroundExosome: A novel neurotransmission modulator or non-canonical neurotransmitter?
Xia, X., Wang, Y., Qin, Y., Zhao, S., & Zheng, J. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101558 · Cited by 109 · cited 1×
“The neurotransmitters then bind to receptors on the postsynaptic neuron to create the electrical response [3], enabling neurotransmission.”
BackgroundStructure-based discovery of conformationally selective inhibitors of the serotonin transporter
Singh, I., Seth, A., Billesbølle, C. B., Bráz, J. M., Rodriguiz, R. M., Roy, K., Bekele, B., Craik, V., Huang, X., Boytsov, D., et al. (2023) · Cell · doi:10.1016/j.cell.2023.04.010 · Cited by 106
Kamachi, T., Kihara, N., Shiota, Y., & Yoshizawa, K. (2005) · Inorganic Chemistry · doi:10.1021/ic048477p · Cited by 99 · cited 2×
“For instance, Kamachi et al. [63] concluded that copper-superoxo, -hydroperoxo, and -oxo species can detach a hydrogen atom at the benzylic position of dopamine with activation energies of 17, 40, and 4 kcal/mol, respectively [63].”
BackgroundMethodMolecular dynamics of dopamine at the D2 receptor.
Dahl, S. G., Edvardsen, Ø., & Sylte, I. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.18.8111 · Cited by 96 · cited 2×
“For instance, in 1991, Dahl et al. [44] performed a detailed MD simulation investigation of the D2 dopamine receptor.”
In Silico Studies in Drug Research Against Neurodegenerative Diseases
Makhouri, F. R., & Ghasemi, J. B. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170823095628 · Cited by 89 · cited 4×
“Indeed, QM/MM methods have been widely employed in recent years to study chemical processes such as enzyme-inhibitor interactions [39].”
BackgroundMethodInfluentialHiramatsu, M., & Cho, A. K. (1990) · Neuropharmacology · doi:10.1016/0028-3908(90)90012-g · Cited by 81
Huot, P., Johnston, T. H., Lewis, K. D., Koprich, J. B., Reyes, M. G., Fox, S. H., Piggott, M. J., & Brotchie, J. M. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.1171-11.2011 · Cited by 81
Computational Studies of Aflatoxin B1 (AFB1): A Review
Martínez, J. O., Rodríguez, M. H., Méndez‐Albores, A., Téllez‐Isaías, G., Jiménez, E. M., Nicolás‐Vázquez, M. I., & Miranda, R. (2023) · Toxins · doi:10.3390/toxins15020135 · Cited by 81
Effect fingerprinting of new psychoactive substances (NPS): What can we learn from in vitro data?
Hondebrink, L., Zwartsen, A., & Westerink, R. H. S. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.022 · Cited by 80 · cited 2×
“Indeed, the diversity of reported in vitro data, the occurrence of multiple drug targets (combination of multiple receptor signals) for a single behavioral outcome, the limited availability of suitable experi ental techniques, and ethical considerations regarding human studies further complicate the acquisition of rel…”
BackgroundStructural genomics of the human dopamine receptor system
Xu, P., Huang, S., Krumm, B. E., Zhuang, Y., Mao, C., Zhang, Y., Wang, Y., Huang, X.-P., Liu, Y., He, X., et al. (2023) · Cell Research · doi:10.1038/s41422-023-00808-0 · Cited by 78 · cited 1×
“The latest crystallographic data on dopamine receptors was published recently, which reports cryogenic electron microscopy structures of all five subtypes of human dopamine receptors (D1–D5) in complex with G protein [53].”
BackgroundPsychotomimetic drugs; chemical and pharmacological aspects.
Hofmann, A. A. (1959) · PubMed · Cited by 67
Entactogens: How the Name for a Novel Class of Psychoactive Agents Originated
Nichols, D. E. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.863088 · Cited by 66 · cited 5×
“Unexpected SARs f some phe ethylamines (entactogens) [9].”
BackgroundInfluentialInsights into the mechanism and pharmacology of neurotransmitter sodium symporters
Navratna, V., & Gouaux, E. (2019) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2019.03.011 · Cited by 65 · cited 1×
“Meanwhile, Navratna and Gouaux considered the structures and mechanisms of eukaryotic Neurotransmitter Sodium Sym-porters (NSSs), specifically the molecular basis for ligand recognition and their transport mechanism [60].”
BackgroundComputational modeling for the design and development of nano based drug delivery systems
Ashwini, T., Narayan, R., Shenoy, P. A., & Nayak, U. Y. (2022) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2022.120596 · Cited by 64 · cited 2×
“As highlighted in Figure 2, this is because there have also been considerable advances in the power and applicability of such in silico methods, enabling their application to such diverse areas as the molecular basis of cancer biochemistry to virology, including COVID-19 [22].”
BackgroundStereospecific requirements for hallucinogenesis
Shulgin, A. T. (1973) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1973.tb10642.x · Cited by 58 · cited 4×
“For example, it has been reported that for lysergic acid diethylamide (LSD) [31], 4-bromo-2,5-dimethoxyphenylisopropylamin (DOB) [30], and 4-methyl-2,5-di et la ine (DOM, STP) [32], the active enantiomer is the “R” configuration.”
BackgroundInfluentialCorrection: Psychedelics and the Human Receptorome
Ray, T. S. (2010) · PLoS ONE · doi:10.1371/annotation/e580a864-cf13-40c2-9bd9-b9687a6f0fe4 · Cited by 58
Kaufmann, K. W., Dawson, E. S., Henry, L. K., Field, J. R., Blakely, R., & Meiler, J. (2008) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.22178 · Cited by 56 · cited 1×
“Meanwhile, in 2009, Kaufmann et al. used the Rosetta Ligand docking program to identify and determine the binding site of 5-HT on SERT [46].”
Method4-Bromo-2,5-Dimethoxyphenylisopropylamine, a New Centrally Active Amphetamine Analog
Shulgin, A. T., Sargent, T., & Naranjo, C. L. (2008) · Pharmacology · doi:10.1159/000136181 · Cited by 52 · cited 2×
“) [31], 4-bromo-2,5-dimethoxy-phenylisopropylamine (DOB) [30], and 4-methyl-2,5-dimethoxyphenylisopropylamine (DOM, STP) [32], the active enantiomer is the “R” con fi guration.”
BackgroundGupta, S. P., Singh, P., & Bindal, M. C. (1983) · Chemical Reviews · doi:10.1021/cr00058a003 · Cited by 51 · cited 1×
“In 1983, Gupta et al. [79] published arguably one of the first reviews of QSAR studies of hallucinogens.”
BackgroundŠkuta, C., Cortés‐Ciriano, I., Dehaen, W., Kříž, P., van Westen, G. J. P., Tetko, I. V., Bender, A., & Svozil, D. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00443-6 · Cited by 51 · cited 1×
“Further details on performing computer-aided drug design have been published in several recent reviews [94,95], while a text summary is also provided in the Supporting Information (Table S1).”
Lam, Y.-H., Abramov, Y., Ananthula, R. S., Elward, J. M., Hilden, L. R., Nilsson Lill, S. O., Norrby, P.-O., Ramirez, A., Sherer, E. C., Mustakis, J., et al. (2020) · Organic Process Research & Development · doi:10.1021/acs.oprd.0c00222 · Cited by 48
(±)-MDMA and its enantiomers: potential therapeutic advantages of R(−)-MDMA
Pitts, E. G., Curry, D. W., Hampshire, K. N., Young, M. B., & Howell, L. L. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4812-5 · Cited by 47 · cited 1×
“Amphetamine MDMA (3,4-methylenedioxymethamphetamine) is one such species, with R-and S-MDMA being reported to exhibit different activities towards CNS targets [72,86–88].”
BackgroundBenefits of hybrid QM/MM over traditional classical mechanics in pharmaceutical systems
Kar, R. K. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103374 · Cited by 47 · cited 1×
“The surrounding region, the low layer, is then modeled at a lower and thus computationally cheaper level of theory, commonly molecular mechanics (MM) [34].”
BackgroundPsychotomimetic agents related to mescaline
Shulgin, A. T. (1963) · Cellular and Molecular Life Sciences · doi:10.1007/bf02171586 · Cited by 46
Nadal‐Gratacós, N., Alberto‐Silva, A. S., Rodríguez-Soler, M., Urquizu, E., Espinosa‐Velasco, M., Jäntsch, K., Holy, M., Batllori, X., Berzosa, X., Pubill, D., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.749429 · Cited by 44
Neuropharmacology of New Psychoactive Substances (NPS)
Wiley, J. L., Glennon, R. A., & Baumann, M. H. (2017) · Current topics in behavioral neurosciences · doi:10.1007/978-3-319-52444-3 · Cited by 43
Maršavelski, A., & Vianello, R. (2017) · Chemistry - A European Journal · doi:10.1002/chem.201605430 · Cited by 42
Gadaleta, D., Sp̂înu, N., Roncaglioni, A., Cronin, M., & Benfenati, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063053 · Cited by 39 · cited 1×
“Hallucinogenic activity is a result of multiple drug-target (receptor and transporter) interactions, and if the response (experimental data) is an adverse outcome rather than a single biochemical key event, QSAR may fail, especially if the dataset is relatively small [80].”
BackgroundA quantitative model of amphetamine action on the 5‐ HT transporter
Sandtner, W., Schmid, D., Schicker, K. W., Gerstbrein, K., Koenig, X., Mayer, F. P., Boehm, S., Freissmuth, M., & Sitte, H. H. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12520 · Cited by 36 · cited 2×
“…on psychedelic activity were Meanwhile, the effects of structure and stereoisomerism on psychedelic activity were extensively discussed in the “Quantitative Structure-Activity Relationships (QSAR) of Narcotic Analgesics, Narcotic Antagonists, and Hallucinogens Conference” in 1978 [11].”
BackgroundAmphetamine Derivatives as Monoamine Oxidase Inhibitors
Reyes-Parada, M. I., Iturriaga‐Vásquez, P., & Cassels, B. K. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01590 · Cited by 35 · cited 2×
“MAO exists in two isoforms (isozymes), MAO-A and MAO-B; both are outer mitochondrial membrane-bound flavoproteins [83].”
BackgroundRecent Advances and Challenges of the Drugs Acting on Monoamine Transporters
Xue, W., Fu, T., Zheng, G., Tu, G., Zhang, Y., Yang, F., Tao, L., Yao, L., & Zhu, F. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181009123218 · Cited by 34 · cited 2×
“For example, for the bacterial leucine transporter (LeuT) complexed with clomipramine, there are presently over 100 experimentally determined structures or computational models published, which also highlight a substantial degree of variability in hMATS-ligand recognition [59].”
BackgroundQSAR-derived affinity fingerprints (part 2): modeling performance for potency prediction
Cortés‐Ciriano, I., Škuta, C., Bender, A., & Svozil, D. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00444-5 · Cited by 31 · cited 1×
“Further details on performing computer-aided drug design have been published in several recent reviews [94,95], while a text summary is also provided in the Supporting Information (Table S1).”
Borroto‐Escuela, D. O., Ambrogini, P., Narváez, M., Liberto, V. D., Beggiato, S., Ferraro, L., Fores‐Pons, R., Alvarez‐Contino, J. E., López‐Salas, A., Mudò, G., et al. (2021) · Cells · doi:10.3390/cells10081902 · Cited by 30 · cited 2×
“Since there is a direct relationship between the chemical processes in the CNS and these diseases, a deeper understanding of the molecular mechanism would enhance prevention and treatment [7,8].”
BackgroundLarsen, M., Plenge, P., Andersen, J., Eildal, J. N. N., Kristensen, A. S., Bøgesø, K. P., Gether, U., Strømgaard, K., Bang‐Andersen, B., & Loland, C. J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13411 · Cited by 29
Multi-Parameter Optimization: Identifying High Quality Compounds with a Balance of Properties
Segall, M. (2012) · Current Drug Metabolism · doi:10.2174/138920012799362864 · Cited by 27
Structural insights into the ligand binding and Gi coupling of serotonin receptor 5-HT5A
Tan, Y., Xu, P., Huang, S., Yang, G., Zhou, F., He, X., Ma, H., Xu, H. E., & Jiang, Y. (2022) · Cell Discovery · doi:10.1038/s41421-022-00412-3 · Cited by 27
Moinul, M., Khatun, S., Amin, S. A., Jha, T., & Gayen, S. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115301 · Cited by 22 · cited 2×
“Indeed, computational modeling and simulations of possible therapeutics have shown great potential to facilitate drug discovery and development [23].”
BackgroundCharge-transfer interactions in the inhibition of MAO-A by phenylisopropylamines – a QSAR study
Vallejos, G. A., Rezende, M. C., & Cassels, B. K. (2002) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1016344030772 · Cited by 21 · cited 1×
“One of the early studies in this field was conducted in 2002 by Vallejos et al. [84], where they investigated the interaction between phenylisopropylamine compounds and the enzyme monoamine oxidase A (MAO-A).”
BackgroundFresqui, M., Ferreira, M. M. C., & Trsic, M. (2012) · Analytica Chimica Acta · doi:10.1016/j.aca.2012.11.004 · Cited by 21 · cited 1×
“For example, Fresqui et al. [89] have used QSAR to investigate the influence of R - and S -enantiomers (stereoisomers) of a range of amphetamines on MAO.”
MethodEditorial on the FDA Report on “Successes and Opportunities in Modeling & Simulation for FDA”
Ahmed, K. B. R., Pathmanathan, P., Kabadi, S. V., Drgon, T., & Morrison, T. M. (2022) · Annals of Biomedical Engineering · doi:10.1007/s10439-022-03112-x · Cited by 20 · cited 2×
“…dementia, epilepsy, and Parkinson’s) through SARs and bioinformatics data analysis is now seen as an essential tool towards their treat-ment [68]. and valuable part of toxicology since the mid-1970s [73,74] and an extremely important part in the twenty-first century, as Cramer et al.…”
BackgroundMethodFloresta, G., & Abbate, V. (2021) · RSC Advances · doi:10.1039/d1ra01335a · Cited by 16
Combs, S. A., Kaufmann, K. W., Field, J. R., Blakely, R., & Meiler, J. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100066p · Cited by 13 · cited 1×
“In 2011, they used the same approach to also study S-citalopram binding with human SERT and reported that a tyrosine (Tyr95) and a glutamate (Glu344) residue are important for binding [47].”
Llabrés, S., Garcia‐Ratés, S., Cristóbal‐Lecina, E., Riéra, A., Borrell, J. I., Camarasa, J., Pubill, D., Luque, F. J., & Escubedo, E. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.04.044 · Cited by 12 · cited 1×
“Amphetamine MDMA (3,4-methylenedioxymethamphetamine) is one such species, with R-and S-MDMA being reported to exhibit different activities towards CNS targets [72,86–88].”
BackgroundJha, P., Ragnarsson, L. K. N., & Lewis, R. J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00217 · Cited by 10 · cited 1×
“4 of 20 Molecules 2023 , 28 , x FOR PEER REVIEW 4 of 21 interpreting trends, Structure-Activity Relationships, and the identi fi cation of some mechanisms of the CNS [17,24–27].”
Background3D-QSAR studies of D3R antagonists and 5-HT1AR agonists
Ma, J., Zhang, H., Zhang, X., & Lei, M. (2018) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2018.10.013 · Cited by 9 · cited 1×
“Recently, Ma et al. [82] developed and used advanced predictive 3D-QSAR models to design and modify compounds that target two specific receptors in the brain: the dopamine D3 receptor (D3R) and the serotonin receptor (5-HT1AR).”
BackgroundSaganuwan, S. A. (2019) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/1871524919666190624150214 · Cited by 9 · cited 1×
“Chirality as it pertains to the properties and roles of ligands and therapeutic drugs has attracted considerable attention, especially in neurochemistry [85].”
BackgroundSelçuk, B., Erol, İ., Durdağı, S., & Adebalı, O. (2022) · Life Science Alliance · doi:10.26508/lsa.202201439 · Cited by 9
Si̇yah, P., Durdağı, S., & Aksoydan, B. (2023) · Biophysical Journal · doi:10.1016/j.bpj.2022.11.942 · Cited by 9 · cited 1×
“4 of 20 Molecules 2023 , 28 , x FOR PEER REVIEW 4 of 21 interpreting trends, Structure-Activity Relationships, and the identi fi cation of some mechanisms of the CNS [17,24–27].”
BackgroundZhou, K., Cao, X., Bautista, J., Chen, Z., Hershey, N. D., Ludwig, R. T., Tao, L., Zeng, M., & Das, T. K. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.08.018 · Cited by 8
Islas, Á. A., Moreno, L. G., & Scior, T. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e07784 · Cited by 8 · cited 3×
“Several studies have examined the mechanistic details of MATs within the context of their roles in the CNS [12,14].”
BackgroundMethodResultMcCarthy, M. J., Chushak, Y. G., & Gearhart, J. M. (2022) · Computational Toxicology · doi:10.1016/j.comtox.2022.100238 · Cited by 8
Effects of the N-Terminal Dynamics on the Conformational States of Human Dopamine Transporter
Xu, L., & Chen, L. Y. (2021) · Biophysical Chemistry · doi:10.1016/j.bpc.2022.106765 · Cited by 7
Catalani, V., Floresta, G., Botha, M., Corkery, J., Guirguis, A., Vento, A., Abbate, V., & Schifano, F. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14119 · Cited by 7
Guirguis, A. (2022) · Cronfa (Swansea University) · Cited by 6
Review of 3D templates for in silico homology models of MATs: improved 3D model of hDAT
Jones, C. B., & Dukat, M. (2022) · Medicinal Chemistry Research · doi:10.1007/s00044-022-02863-5 · Cited by 4 · cited 3×
“Docking Docking as a tool to both help identify Homology modeling has made great strides in recent years [43]. possible binding sites and potential ligands has become a very A detailed analysis and comparison of current known monoamine transporter (MAT) crystal structures and homology modeling…”
BackgroundInfluentialThe Hydrolysis Rate of Paraoxonase-1 Q and R Isoenzymes: An In Silico Study Based on In Vitro Data
Karabulut, S., Mansour, B., Casañola‐Martín, G. M., Rasulev, B., & Gauld, J. W. (2022) · Molecules · doi:10.3390/molecules27206780 · Cited by 3
Cholanians, A. B., Phan, A. V., Lau, S. S., & Monks, T. J. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfz085 · Cited by 2
Research works printed but not linked: 2
- Shulgin A.T. Psychotomimetic Drugs: Structure-Activity Relationships Iversen L.L. Iversen S.D. Snyder S.H. Springer Boston, MA, USA 1978 978-1-4757-0510-2
- Gad S.C. QSAR Encyclopedia of Toxicology 3rd ed. Elsevier Inc. Amsterdam, The Netherlands 2014 Volume 4 1 9 9780123864543
Cited by
Alnuqaydan, A. M. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1439027 · Cited by 84
Alhawarri, M. B., & Olimat, S. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010299804240324140017 · Cited by 11
Karabulut, S., Kaur, H., & Gauld, J. W. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00677 · Cited by 6
Tanouti, I.-A., Ezzemani, W., Ahmad, S., Redouane, S., Charoute, H., Pineau, P., Fellah, H., & Ezzikouri, S. (2025) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2025.100067 · Cited by 1
Sobańska, A. W., Sobański, A. M., & Brzezińska, E. (2026) · Molecules · doi:10.3390/molecules31020212 · Cited by 1
“Such restrictions limit the research using these compounds—human studies are replaced by animal (mainly rodent) models, e.g., head-twitch response assay [16] and in silico investigations [17].”
Metadata
- Authors
- Karabulut, S., Kaur, H., & Gauld, J. W.
- Affiliations
- University of Windsor (CA)
- Pharmala Biotech, 82 Richmond Street E, Toronto, ON M5C 1P1, Canada
- Corresponding author
- Gauld, James W.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2023-08-09
- Volume
- 28
- Issue
- 16
- Pages
- 5966
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC10459288
- OpenAlex
- W4385697551
- Cited by
- 8
- References
- 99
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 3
- FWCI
- 0.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Scholarship at UWindsor (University of Windsor) (submittedVersion)
- Funders
- Natural Sciences and Engineering Research Council (NSERC) of Canada (04840-2018, IT29298)
- MITACS (04840-2018, IT29298)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Physical Sciences › Materials Science › Materials Chemistry › Machine Learning in Materials Science
- Keywords
- psychedelics, computational drug discovery, computational chemistry, central nervous system, mental illness, neurological disorders, drug prediction, bioinformatics, prediction model, QSAR
- MeSH terms
- Central Nervous System, Drug Compounding, Hallucinogens, Computational Biology, Genomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.